Rheumatoid factor and anti-cyclic citrullinated peptide antibody levels decline in rheumatoid arthritis patients treated with Janus kinase inhibitors or biological disease-modifying anti-rheumatic drugs.

ABSTRACT:

Objective

We aimed to investigate the rate of decline in serum anti-cyclic citrullinated peptide antibody (ACPA) and rheumatoid factor (RF) levels in rheumatoid arthritis (RA) patients treated with Janus kinase inhibitors (JAKis) compared with biological disease-modifying anti-rheumatic drugs (bDMARDs) and examine factors associated with this decline.

Methods

Patients with RA who had data on ACPA and RF levels before and after JAKis or bDMARDs treatment were included in this single-center retrospective study. A reduction in ACPA and RF levels of ≥20% was defined as a decline.

Results

In total, 201 patients (mean age 53 years; 10% males) were identified. After a mean 4 years of treatment with JAKis, tumor necrosis factor inhibitors, abatacept, or tocilizumab, 43.8%, 37

SUBMITTER: Kim BY 

PROVIDER: S-EPMC12455031 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature